DK3483143T3 - Piperidinonderivater som mdm2-inhibitorer til behandlingen af kræft - Google Patents

Piperidinonderivater som mdm2-inhibitorer til behandlingen af kræft Download PDF

Info

Publication number: DK3483143T3
Authority: DK; Denmark
Prior art keywords: cancer; treatment; piperidine derivatives; mdm2 inhibitors; mdm2
Prior art date: 2010-06-04

Application number

DK18197155.7T

Other languages

English (en)

Inventor

Jeffrey Deignan

Jason A Duquette

John Eksterowicz

Benjamin Fisher

Brian Matthew Fox

Jiasheng Fu

Zice Fu

Lopez De Turiso Felix Gonzalez

Jr Michael William Gribble

Darin James Gustin

Julie Anne Heath

Xin Huang

Xianjun Jiao

Michael Johnson

Frank Kayser

David John Kopecky

Sujen Lai

Yihong Li

Zhihong Li

Jiwen Liu

Michael David Bartberger

Buenrostro Ana Gonzalez

Hilary Place Beck

Xiaoqi Chen

Richard Victor Connors

Jonathan Dante Low

Brian Stuart Lucas

Zhihua Ma

Lawrence R Mcgee

Joel Mcintosh

Julio Cesar Medina

Jeffrey Thomas Mihalic

Steven Howard Olson

Yosup Rew

Philip Marley Roveto

Daqing Sun

Xiaodong Wang

Yingcai Wang

Xuelei Yan

Ming Yu

Jiang Zhu

Dustin Mcminn

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-04

Filing date

2011-06-03

Publication date

2024-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44504412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3483143(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-06-03 Application filed by Amgen Inc filed Critical Amgen Inc

2024-01-15 Application granted granted Critical

2024-01-15 Publication of DK3483143T3 publication Critical patent/DK3483143T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Virology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK18197155.7T 2010-06-04 2011-06-03 Piperidinonderivater som mdm2-inhibitorer til behandlingen af kræft DK3483143T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US35182710P	2010-06-04	2010-06-04
US35232210P	2010-06-07	2010-06-07
US201161452578P	2011-03-14	2011-03-14
EP15159363.9A EP2927213B1 (en)	2010-06-04	2011-06-03	Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer

Publications (1)

Publication Number	Publication Date
DK3483143T3 true DK3483143T3 (da)	2024-01-15

Family

ID=44504412

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK15159363.9T DK2927213T3 (da)	2010-06-04	2011-06-03	Piperidinonderivater som MDM2-inhibitorer til behandling af kræft
DK18197155.7T DK3483143T3 (da)	2010-06-04	2011-06-03	Piperidinonderivater som mdm2-inhibitorer til behandlingen af kræft
DK11726581.9T DK2576510T3 (da)	2010-06-04	2011-06-03	Piperidinonderivater som mdm2-inhibitorer til behandlingen af cancer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK15159363.9T DK2927213T3 (da)	2010-06-04	2011-06-03	Piperidinonderivater som MDM2-inhibitorer til behandling af kræft

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK11726581.9T DK2576510T3 (da)	2010-06-04	2011-06-03	Piperidinonderivater som mdm2-inhibitorer til behandlingen af cancer

Country Status (41)

Country	Link
US (10)	US8569341B2 (da)
EP (4)	EP2927213B1 (da)
JP (3)	JP5420797B2 (da)
KR (9)	KR20190058694A (da)
CN (2)	CN103180296B (da)
AR (1)	AR082763A1 (da)
AU (1)	AU2011261263C1 (da)
BR (2)	BR112012030923B8 (da)
CA (4)	CA3207676A1 (da)
CL (2)	CL2012003415A1 (da)
CO (1)	CO6710897A2 (da)
CR (1)	CR20120659A (da)
CY (1)	CY1121265T1 (da)
DK (3)	DK2927213T3 (da)
EA (1)	EA023004B1 (da)
ES (3)	ES2971445T3 (da)
FI (1)	FI3483143T3 (da)
HR (3)	HRP20240055T1 (da)
HU (2)	HUE041488T2 (da)
IL (7)	IL277579B (da)
JO (1)	JO2998B1 (da)
LT (2)	LT2927213T (da)
MA (1)	MA34342B1 (da)
ME (2)	ME02150B (da)
MX (2)	MX343587B (da)
MY (1)	MY202394A (da)
NZ (2)	NZ604074A (da)
PE (1)	PE20130229A1 (da)
PH (2)	PH12012502410A1 (da)
PL (3)	PL2927213T3 (da)
PT (3)	PT2927213T (da)
RS (3)	RS65141B1 (da)
SG (4)	SG10201604817QA (da)
SI (3)	SI2927213T1 (da)
SM (3)	SMT201900099T1 (da)
TN (1)	TN2012000559A1 (da)
TW (3)	TWI582076B (da)
UA (1)	UA110481C2 (da)
UY (2)	UY39338A (da)
WO (1)	WO2011153509A1 (da)
ZA (1)	ZA201400948B (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0811643D0 (en)	2008-06-25	2008-07-30	Cancer Rec Tech Ltd	New therapeutic agents
JO2998B1 (ar) *	2010-06-04	2016-09-05	Amgen Inc	مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20130267699A1 (en)	2011-06-24	2013-10-10	California Institute Of Technology	Quaternary heteroatom containing compounds
US8822679B2 (en) *	2011-06-24	2014-09-02	California Institute Of Technology	Quaternary heteroatom containing compounds
US9376425B2 (en)	2011-09-27	2016-06-28	Amgen, Inc.	Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
JP6495654B2 (ja)	2011-10-24	2019-04-03	アサナバイオサイエンシズ，リミティドライアビリティカンパニー	シクロヘキシルアミン類
EP2847177B1 (en)	2012-05-09	2017-10-11	Boehringer Ingelheim International GmbH	Methods for making oxetan-3-ylmethanamines
KR102196882B1 (ko)	2012-12-20	2020-12-30	머크 샤프 앤드 돔 코포레이션	Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014130470A1 (en) *	2013-02-19	2014-08-28	Amgen Inc.	Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
US11407721B2 (en)	2013-02-19	2022-08-09	Amgen Inc.	CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014134201A1 (en) *	2013-02-28	2014-09-04	Amgen Inc.	A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
MX374513B (es) *	2013-03-14	2025-03-06	Amgen Inc	Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
CN105358530A (zh)	2013-06-10	2016-02-24	美国安进公司	制备mdm2抑制剂的方法及其结晶形式
BR112016010564A2 (pt)	2013-11-11	2017-10-10	Amgen Inc	terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
KR101862955B1 (ko) *	2013-12-05	2018-05-31	에프. 호프만-라 로슈 아게	급성 골수성 백혈병(aml)을 위한 신규한 병용 치료
CA2945527C (en)	2014-04-17	2022-05-17	The Regents Of The University Of Michigan	Mdm2 inhibitors and therapeutic methods using the same
CN103992334A (zh) *	2014-05-29	2014-08-20	中国人民解放军第二军医大学	吲哚酮螺四氢硫代吡喃类抗肿瘤衍生物及其制备方法
WO2016001376A1 (en)	2014-07-03	2016-01-07	Boehringer Ingelheim International Gmbh	New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
RS59111B1 (sr)	2014-08-21	2019-09-30	Boehringer Ingelheim Int	Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori
TW201702218A (zh)	2014-12-12	2017-01-16	美國杰克森實驗室	關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US10421696B2 (en)	2014-12-18	2019-09-24	California Institute Of Technology	Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
CN107922373A (zh)	2015-03-27	2018-04-17	加利福尼亚技术学院	使用低催化剂浓度和稳定的预催化剂的不对称催化脱羧烷基烷基化
GB201517217D0 (en)	2015-09-29	2015-11-11	Astex Therapeutics Ltd And Cancer Res Technology Ltd	Pharmaceutical compounds
GB201517216D0 (en)	2015-09-29	2015-11-11	Cancer Res Technology Ltd And Astex Therapeutics Ltd	Pharmaceutical compounds
KR20240158360A (ko) *	2015-10-09	2024-11-04	베링거 인겔하임 인터내셔날 게엠베하	Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체
WO2017156239A1 (en)	2016-03-11	2017-09-14	California Institute Of Technology	Compositions and methods for acylating lactams
SG11201808728QA (en) *	2016-04-06	2018-11-29	Univ Michigan Regents	Mdm2 protein degraders
KR20180132861A (ko) *	2016-04-12	2018-12-12	더 리젠츠 오브 더 유니버시티 오브 미시간	Bet 단백질 분해제
TWI808055B (zh)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN118436801A (zh)	2016-05-20	2024-08-06	豪夫迈·罗氏有限公司	Protac抗体缀合物及其使用方法
GB201704966D0 (en)	2017-03-28	2017-05-10	Astex Therapeutics Ltd	Pharmaceutical compounds
GB201704965D0 (en)	2017-03-28	2017-05-10	Astex Therapeutics Ltd	Pharmaceutical compounds
EP3480190B1 (en)	2017-11-01	2023-01-04	California Institute of Technology	Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols
US12030879B2 (en)	2018-03-02	2024-07-09	Inflazome Limited	Sulfonyl acetamides as NLRP3 inhibitors
IL319432A (en)	2018-04-30	2025-05-01	Kartos Therapeutics Inc	Methods of treating cancer
AU2019327555B2 (en)	2018-08-31	2025-01-16	Amgen, Inc.	Processes for preparing a MDM2 inhibitor
CN110963958B (zh) *	2018-09-30	2025-10-10	上海长森药业有限公司	一种mdm2抑制剂，及其制备方法、药物组合物和应用
US11214568B2 (en)	2018-10-18	2022-01-04	California Institute Of Technology	Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
WO2020123656A1 (en) *	2018-12-11	2020-06-18	Kartos Therapeutics	Methods and compositions of treating an ophthalmic condition
GB201919219D0 (en)	2019-12-23	2020-02-05	Otsuka Pharma Co Ltd	Cancer biomarkers
US20230064976A1 (en) *	2020-01-23	2023-03-02	Ascentage Pharma (Suzhou) Co., Ltd.	Amorphous form or crystalline form of 2-indolinolinololylspironone compounds or their salts, solvent complexes
JP2023515979A (ja)	2020-02-27	2023-04-17	シンジェンタクロッププロテクションアクチェンゲゼルシャフト	殺有害生物的に活性なジアジン－ビスアミド化合物
KR20230005160A (ko)	2020-03-19	2023-01-09	카이메라 쎄라퓨틱스 인코포레이티드	Mdm2 분해제 및 이의 용도
EP4204812A2 (en)	2020-08-27	2023-07-05	Otsuka Pharmaceutical Co., Ltd.	Biomarkers for cancer therapy using mdm2 antagonists
CN112213428A (zh) *	2020-10-13	2021-01-12	辽宁科技大学	一种超临界co2中进行非催化乙酰基化反应及其在线检测方法
WO2022159644A1 (en)	2021-01-23	2022-07-28	Newave Pharmaceutical Inc.	Spirocyclic mdm2 modulator and uses thereof
GB202103080D0 (en)	2021-03-04	2021-04-21	Otsuka Pharma Co Ltd	Cancer biomarkers
WO2023056069A1 (en)	2021-09-30	2023-04-06	Angiex, Inc.	Degrader-antibody conjugates and methods of using same
US20260014260A1 (en) *	2022-05-24	2026-01-15	Newave Pharmaceutical Inc.	Mdm2 degrader
US20250352535A1 (en) *	2022-06-06	2025-11-20	Kymera Therapeutics, Inc.	Mdm2 degraders and uses thereof
CN115322126B (zh) *	2022-09-13	2023-04-28	九江学院	一种多芳烃类化合物及其制备方法和应用
WO2024240858A1 (en)	2023-05-23	2024-11-28	Valerio Therapeutics	Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1016828A (en)	1961-11-13	1966-01-12	Mcneilab Inc	Substituted morpholines and process for preparing same
DE3246148A1 (de)	1982-12-14	1984-06-14	Troponwerke GmbH & Co KG, 5000 Köln	Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO1995023135A1 (en)	1991-03-07	1995-08-31	Fisons Corporation	Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity
US5334720A (en)	1991-03-07	1994-08-02	Fisons Corporation	Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
WO1996006095A1 (en)	1994-08-19	1996-02-29	Abbott Laboratories	Endothelin antagonists
PT885215E (pt)	1996-02-13	2006-08-31	Abbott Lab	Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
US6159990A (en)	1997-06-18	2000-12-12	Synaptic Pharmaceutical Corporation	Oxazolidinones as α1A receptor antagonists
TR200000993T2 (tr)	1997-08-04	2000-12-21	Abbott Laboratories	Endotelin antagonistleri.
AU1910299A (en)	1997-12-18	1999-07-05	Eli Lilly And Company	Peptidomimetic template-based combinatorial libraries
US6770658B2 (en)	1998-09-09	2004-08-03	Inflazyme Pharmaceuticals Ltd.	Substituted γ-phenyl-Δ-lactams and uses related thereto
US7214540B2 (en)	1999-04-06	2007-05-08	Uab Research Foundation	Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en)	1999-06-18	2003-10-07	The Regents Of The University Of California	Method for screening microcrystallizations for crystal formation
US7195670B2 (en)	2000-06-27	2007-03-27	California Institute Of Technology	High throughput screening of crystallization of materials
US7052545B2 (en)	2001-04-06	2006-05-30	California Institute Of Technology	High throughput screening of crystallization of materials
WO2002017912A1 (en)	2000-08-31	2002-03-07	Abbott Laboratories	Endothelin antagonists
AU2002228598A1 (en)	2000-11-20	2002-06-03	Parallel Synthesis Technologies, Inc.	Methods and devices for high throughput crystallization
JP2004518688A (ja)	2001-01-30	2004-06-24	ブリストル−マイヤーズ　スクイブ　カンパニー	ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法
ATE409181T1 (de)	2001-05-08	2008-10-15	Univ Yale	Proteomimetische verbindungen und verfahren
WO2002094787A1 (en)	2001-05-23	2002-11-28	Ucb, S.A.	2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
PL370823A1 (en)	2001-12-18	2005-05-30	F.Hoffmann-La Roche Ag	Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
US6860940B2 (en)	2002-02-11	2005-03-01	The Regents Of The University Of California	Automated macromolecular crystallization screening
US6916833B2 (en) *	2003-03-13	2005-07-12	Hoffmann-La Roche Inc.	Substituted piperidines
US7425638B2 (en)	2003-06-17	2008-09-16	Hoffmann-La Roche Inc.	Cis-imidazolines
JP4814228B2 (ja)	2004-05-18	2011-11-16	エフ．ホフマン−ラロシュアーゲー	新規ｃｉｓ−イミダゾリン
US7893278B2 (en)	2004-06-17	2011-02-22	Hoffman-La Roche Inc.	CIS-imidazolines
EP1809282B1 (en)	2004-10-18	2013-01-09	Amgen, Inc	Thiadiazole compounds and methods of use
CA2599476A1 (en)	2005-03-16	2006-09-21	F. Hoffmann-La Roche Ag	Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments
AU2006232517A1 (en)	2005-04-04	2006-10-12	Eisai R&D Management Co., Ltd.	Dihydropyridine compounds and compositions for headaches
JP4870778B2 (ja)	2005-12-01	2012-02-08	エフ．ホフマン−ラロシュアーゲー	抗ガン剤として使用されるｐ５３およびｍｄｍ２タンパク質間の相互作用の阻害剤としての２，４，５−トリフェニルイミダゾリン誘導体
EP1987000A2 (en) *	2006-01-13	2008-11-05	Schering Corporation	Diaryl piperidines as cb1 modulators
WO2007084391A2 (en)	2006-01-18	2007-07-26	Amgen Inc.	Thiazole compounds as protein kinase b ( pkb) inhibitors
US20070213341A1 (en)	2006-03-13	2007-09-13	Li Chen	Spiroindolinone derivatives
GB0606283D0 (en)	2006-03-29	2006-05-10	Cyclacel Ltd	Process
BRPI0713119A2 (pt) *	2006-06-30	2012-04-17	Schering Corp	piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
JP2009543865A (ja)	2006-07-19	2009-12-10	ユニバーシティオブジョージアリサーチファウンデーション，インコーポレーテッド	ピリジノンジケト酸：併用療法におけるｈｉｖ複製の阻害剤
WO2008021338A2 (en)	2006-08-15	2008-02-21	Wyeth	Tricyclic oxazolidone derivatives useful as pr modulators
US20080045560A1 (en)	2006-08-15	2008-02-21	Wyeth	Pyrrolidine and related derivatives useful as PR modulators
US8820639B2 (en)	2006-11-03	2014-09-02	Assa Abloy Ab	Security feature RFID card
TW200831080A (en)	2006-12-15	2008-08-01	Irm Llc	Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
EP2137150A1 (en) *	2007-03-12	2009-12-30	Biolipox AB	Piperidinones useful in the treatment of inflammation
GB0722769D0 (en)	2007-11-21	2008-01-02	Biolipox Ab	New compounds
EP2139882B1 (en)	2007-03-23	2013-12-25	Amgen Inc.	3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
DK2137186T3 (da)	2007-03-23	2016-04-18	Amgen Inc	Heterocykliske forbindelser og deres anvendelser
EP2132207A2 (en)	2007-03-23	2009-12-16	Amgen Inc.	Heterocyclic compounds and their uses
EA200901212A1 (ru) *	2007-03-29	2010-04-30	Новартис Аг	3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
US7625895B2 (en)	2007-04-12	2009-12-01	Hoffmann-Le Roche Inc.	Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en)	2007-04-20	2008-10-30	University Of Pittsburg-Of The Commonwealth System Of Higher Education	Selective and dual-action p53/mdm2/mdm4 antagonists
US7834179B2 (en)	2007-05-23	2010-11-16	Hoffmann-La Roche Inc.	Spiroindolinone derivatives
WO2009004430A1 (en)	2007-06-29	2009-01-08	Pfizer Inc.	N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
CN101809002B (zh)	2007-07-09	2013-03-27	阿斯利康(瑞典)有限公司	用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
EP2173728A2 (en)	2007-07-17	2010-04-14	Amgen Inc.	Heterocyclic modulators of pkb
US7919504B2 (en)	2007-07-17	2011-04-05	Amgen Inc.	Thiadiazole modulators of PKB
TW200911798A (en)	2007-08-02	2009-03-16	Amgen Inc	PI3 kinase modulators and methods of use
RU2487127C2 (ru)	2007-10-09	2013-07-10	Ф.Хоффманн-Ля Рош Аг	Хиральные цис-имидазолины
US7776875B2 (en)	2007-12-19	2010-08-17	Hoffman-La Roche Inc.	Spiroindolinone derivatives
AU2008343813B2 (en)	2007-12-19	2012-04-12	Amgen Inc.	Inhibitors of PI3 kinase
EA201001030A1 (ru)	2007-12-19	2011-02-28	Амген Инк.	Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
WO2009082038A2 (en)	2007-12-26	2009-07-02	Eisai R & D Management Co., Ltd.	Ampa receptor antagonists and zonisamide for epilepsy
US20110105488A1 (en)	2008-03-21	2011-05-05	Chlorion Pharma, Inc.	Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
US8389533B2 (en)	2008-04-07	2013-03-05	Amgen Inc.	Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
CA2725014C (en)	2008-05-30	2014-06-17	Amgen Inc.	Inhibitors of pi3 kinase
GB0811643D0 (en)	2008-06-25	2008-07-30	Cancer Rec Tech Ltd	New therapeutic agents
AR073578A1 (es)	2008-09-15	2010-11-17	Priaxon Ag	Pirrolidin-2-onas
MY160424A (en)	2008-09-18	2017-03-15	Hoffmann La Roche	Substituted pyrrolidine-2-carboxyamides.
EP2387570A1 (en)	2009-01-15	2011-11-23	Amgen, Inc	Fluoroisoquinoline substituted thiazole compounds and methods of use
JP2012518037A (ja)	2009-02-18	2012-08-09	アムジエン・インコーポレーテツド	ｍＴＯＲキナーゼ阻害剤としてのインドール／ベンゾイミダゾール化合物
JP2012521354A (ja)	2009-03-20	2012-09-13	アムジエン・インコーポレーテツド	Ｐｉ３キナーゼの阻害薬
US8076482B2 (en)	2009-04-23	2011-12-13	Hoffmann-La Roche Inc.	3,3′-spiroindolinone derivatives
UY32582A (es)	2009-04-28	2010-11-30	Amgen Inc	Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
EP2430013B1 (en)	2009-05-13	2014-10-15	Amgen Inc.	Heteroaryl compounds as pikk inhibitors
CA2765817A1 (en)	2009-06-25	2010-12-29	Amgen Inc.	4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
AU2010265971B2 (en)	2009-06-25	2014-08-14	Amgen Inc.	Heterocyclic compounds and their uses as inhibitors of PI3 K activity
SG176986A1 (en)	2009-06-25	2012-02-28	Amgen Inc	Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
CN102625799A (zh)	2009-06-25	2012-08-01	安姆根有限公司	杂环化合物及其用途
IN2012DN01693A (da)	2009-08-26	2015-06-05	Novartis Ag
US8088815B2 (en)	2009-12-02	2012-01-03	Hoffman-La Roche Inc.	Spiroindolinone pyrrolidines
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
JO2998B1 (ar) *	2010-06-04	2016-09-05	Amgen Inc	مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CN102153557B (zh)	2011-01-21	2013-03-20	中国科学院上海有机化学研究所	具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途
US9376425B2 (en)	2011-09-27	2016-06-28	Amgen, Inc.	Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
WO2014130470A1 (en)	2013-02-19	2014-08-28	Amgen Inc.	Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
WO2014134201A1 (en)	2013-02-28	2014-09-04	Amgen Inc.	A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
MX374513B (es)	2013-03-14	2025-03-06	Amgen Inc	Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
CN105358530A (zh)	2013-06-10	2016-02-24	美国安进公司	制备mdm2抑制剂的方法及其结晶形式

2011
- 2011-06-02 JO JOP/2011/0182A patent/JO2998B1/ar active
- 2011-06-03 EP EP15159363.9A patent/EP2927213B1/en active Active
- 2011-06-03 DK DK15159363.9T patent/DK2927213T3/da active
- 2011-06-03 IL IL277579A patent/IL277579B/en unknown
- 2011-06-03 ME MEP-2015-84A patent/ME02150B/me unknown
- 2011-06-03 CA CA3207676A patent/CA3207676A1/en active Pending
- 2011-06-03 RS RS20240056A patent/RS65141B1/sr unknown
- 2011-06-03 KR KR1020197014475A patent/KR20190058694A/ko not_active Ceased
- 2011-06-03 DK DK18197155.7T patent/DK3483143T3/da active
- 2011-06-03 EP EP22160459.8A patent/EP4092012A1/en active Pending
- 2011-06-03 CA CA3060703A patent/CA3060703C/en active Active
- 2011-06-03 EA EA201291356A patent/EA023004B1/ru not_active IP Right Cessation
- 2011-06-03 PT PT15159363T patent/PT2927213T/pt unknown
- 2011-06-03 SG SG10201604817QA patent/SG10201604817QA/en unknown
- 2011-06-03 CN CN201180038476.9A patent/CN103180296B/zh active Active
- 2011-06-03 RS RS20190184A patent/RS58366B1/sr unknown
- 2011-06-03 LT LTEP15159363.9T patent/LT2927213T/lt unknown
- 2011-06-03 TW TW104140967A patent/TWI582076B/zh active
- 2011-06-03 CA CA2799972A patent/CA2799972C/en active Active
- 2011-06-03 UY UY0001039338A patent/UY39338A/es not_active Application Discontinuation
- 2011-06-03 HU HUE15159363A patent/HUE041488T2/hu unknown
- 2011-06-03 PL PL15159363T patent/PL2927213T3/pl unknown
- 2011-06-03 IL IL317703A patent/IL317703A/en unknown
- 2011-06-03 MX MX2016001932A patent/MX343587B/es unknown
- 2011-06-03 PL PL11726581T patent/PL2576510T3/pl unknown
- 2011-06-03 TW TW103105903A patent/TWI519519B/zh active
- 2011-06-03 SM SM20190099T patent/SMT201900099T1/it unknown
- 2011-06-03 PT PT117265819T patent/PT2576510E/pt unknown
- 2011-06-03 ES ES18197155T patent/ES2971445T3/es active Active
- 2011-06-03 MX MX2012014044A patent/MX337178B/es active IP Right Grant
- 2011-06-03 UA UAA201300192 patent/UA110481C2/ru unknown
- 2011-06-03 MA MA35504A patent/MA34342B1/fr unknown
- 2011-06-03 SM SM20240024T patent/SMT202400024T1/it unknown
- 2011-06-03 ME MEP-2019-41A patent/ME03322B/me unknown
- 2011-06-03 KR KR1020207014861A patent/KR20200063255A/ko not_active Ceased
- 2011-06-03 KR KR1020227017268A patent/KR20220083817A/ko not_active Ceased
- 2011-06-03 KR KR1020137000287A patent/KR101456801B1/ko active Active
- 2011-06-03 PT PT181971557T patent/PT3483143T/pt unknown
- 2011-06-03 AR ARP110101928A patent/AR082763A1/es active IP Right Grant
- 2011-06-03 SI SI201131669T patent/SI2927213T1/sl unknown
- 2011-06-03 PE PE2012002267A patent/PE20130229A1/es active IP Right Grant
- 2011-06-03 UY UY0001033430A patent/UY33430A/es unknown
- 2011-06-03 TW TW100119640A patent/TWI433844B/zh active
- 2011-06-03 DK DK11726581.9T patent/DK2576510T3/da active
- 2011-06-03 SI SI201130499T patent/SI2576510T1/sl unknown
- 2011-06-03 SG SG10202006923RA patent/SG10202006923RA/en unknown
- 2011-06-03 WO PCT/US2011/039184 patent/WO2011153509A1/en not_active Ceased
- 2011-06-03 HR HRP20240055TT patent/HRP20240055T1/hr unknown
- 2011-06-03 KR KR1020237037399A patent/KR20230156431A/ko not_active Ceased
- 2011-06-03 NZ NZ604074A patent/NZ604074A/en unknown
- 2011-06-03 CN CN201510205985.6A patent/CN105153014B/zh active Active
- 2011-06-03 PL PL18197155.7T patent/PL3483143T3/pl unknown
- 2011-06-03 CA CA3157177A patent/CA3157177C/en active Active
- 2011-06-03 PH PH1/2012/502410A patent/PH12012502410A1/en unknown
- 2011-06-03 AU AU2011261263A patent/AU2011261263C1/en active Active
- 2011-06-03 MY MYPI2018000697A patent/MY202394A/en unknown
- 2011-06-03 LT LTEP18197155.7T patent/LT3483143T/lt unknown
- 2011-06-03 RS RS20150364A patent/RS54030B1/sr unknown
- 2011-06-03 EP EP18197155.7A patent/EP3483143B1/en active Active
- 2011-06-03 SG SG10202112488SA patent/SG10202112488SA/en unknown
- 2011-06-03 KR KR1020187014728A patent/KR20180059574A/ko not_active Ceased
- 2011-06-03 KR KR1020257008612A patent/KR20250044461A/ko active Pending
- 2011-06-03 US US13/153,345 patent/US8569341B2/en active Active
- 2011-06-03 SI SI201132100T patent/SI3483143T1/sl unknown
- 2011-06-03 FI FIEP18197155.7T patent/FI3483143T3/fi active
- 2011-06-03 ES ES15159363T patent/ES2717306T3/es active Active
- 2011-06-03 JP JP2013513401A patent/JP5420797B2/ja active Active
- 2011-06-03 PH PH12016501048A patent/PH12016501048A1/en unknown
- 2011-06-03 IL IL295076A patent/IL295076B2/en unknown
- 2011-06-03 EP EP20110726581 patent/EP2576510B1/en active Active
- 2011-06-03 ES ES11726581.9T patent/ES2540992T3/es active Active
- 2011-06-03 HR HRP20150704TT patent/HRP20150704T1/hr unknown
- 2011-06-03 BR BR112012030923A patent/BR112012030923B8/pt active IP Right Grant
- 2011-06-03 NZ NZ627385A patent/NZ627385A/en unknown
- 2011-06-03 HU HUE18197155A patent/HUE066050T2/hu unknown
- 2011-06-03 KR KR1020147013519A patent/KR101863407B1/ko active Active
- 2011-06-03 SG SG2012088837A patent/SG186147A1/en unknown
- 2011-06-03 BR BR122020013151-9A patent/BR122020013151B1/pt active IP Right Grant
- 2011-06-03 KR KR1020217016376A patent/KR20210068144A/ko not_active Ceased
2012
- 2012-11-22 IL IL223201A patent/IL223201A/en active IP Right Grant
- 2012-11-27 TN TNP2012000559A patent/TN2012000559A1/en unknown
- 2012-12-04 CL CL2012003415A patent/CL2012003415A1/es unknown
- 2012-12-10 CO CO12223240A patent/CO6710897A2/es active IP Right Grant
- 2012-12-21 CR CR20120659A patent/CR20120659A/es unknown
2013
- 2013-09-12 US US14/025,688 patent/US20140011796A1/en not_active Abandoned
- 2013-09-18 JP JP2013192621A patent/JP5908446B2/ja active Active
2014
- 2014-02-07 ZA ZA2014/00948A patent/ZA201400948B/en unknown
- 2014-06-26 IL IL233411A patent/IL233411A/en active IP Right Grant
- 2014-06-26 US US14/316,586 patent/US9296736B2/en active Active
2015
- 2015-07-14 SM SM201500168T patent/SMT201500168B/xx unknown
2016
- 2016-01-27 US US15/008,342 patent/US9593129B2/en active Active
- 2016-03-22 JP JP2016056518A patent/JP6077695B2/ja active Active
- 2016-06-16 IL IL246296A patent/IL246296A0/en active IP Right Grant
- 2016-07-06 CL CL2016001733A patent/CL2016001733A1/es unknown
2017
- 2017-01-23 US US15/412,804 patent/US20170144971A1/en not_active Abandoned
2018
- 2018-03-21 US US15/927,426 patent/US20190062276A1/en not_active Abandoned
2019
- 2019-02-11 HR HRP20190273TT patent/HRP20190273T1/hr unknown
- 2019-02-13 CY CY20191100192T patent/CY1121265T1/el unknown
- 2019-03-11 IL IL265278A patent/IL265278B/en active IP Right Grant
2020
- 2020-08-03 US US16/983,027 patent/US20210179560A1/en not_active Abandoned
2022
- 2022-02-15 US US17/672,660 patent/US20220169611A1/en not_active Abandoned
2023
- 2023-10-11 US US18/484,675 patent/US20240300892A1/en not_active Abandoned
2025
- 2025-03-04 US US19/070,108 patent/US20260078091A1/en active Pending

Also Published As

Publication number	Publication date
IL295076B2 (en)	2025-05-01
PH12016501048A1 (en)	2017-05-29
RS54030B1 (sr)	2015-10-30
BR112012030923B1 (pt)	2021-12-28
ES2717306T3 (es)	2019-06-20
LT3483143T (lt)	2024-02-12
IL277579A (en)	2020-11-30
SG186147A1 (en)	2013-01-30
US8569341B2 (en)	2013-10-29
ZA201400948B (en)	2015-06-24
SI2927213T1 (sl)	2019-04-30
SG10202006923RA (en)	2020-08-28
BR112012030923B8 (pt)	2022-01-25
PT3483143T (pt)	2024-01-23
BR122020013151B1 (pt)	2022-02-22
CN105153014A (zh)	2015-12-16
JP5420797B2 (ja)	2014-02-19
CR20120659A (es)	2013-03-11
IL295076A (en)	2022-09-01
EA201291356A1 (ru)	2013-06-28
IL265278B (en)	2021-01-31
IL233411A0 (en)	2014-08-31
EP2576510A1 (en)	2013-04-10
FI3483143T3 (fi)	2024-01-15
MX337178B (es)	2016-02-15
SMT201500168B (it)	2015-09-07
LT2927213T (lt)	2019-04-25
KR20140032929A (ko)	2014-03-17
EP3483143B1 (en)	2023-10-18
CA3157177A1 (en)	2011-12-08
JP6077695B2 (ja)	2017-02-08
HRP20240055T1 (hr)	2024-03-29
PT2927213T (pt)	2019-02-21
SMT201900099T1 (it)	2019-02-28
IL233411A (en)	2017-08-31
ES2540992T3 (es)	2015-07-15
US20220169611A1 (en)	2022-06-02
ME03322B (me)	2019-10-20
KR20250044461A (ko)	2025-03-31
US20210179560A1 (en)	2021-06-17
IL246296A0 (en)	2016-07-31
CA2799972C (en)	2020-08-25
BR112012030923A2 (pt)	2016-11-08
IL295076B1 (en)	2025-01-01
TWI433844B (zh)	2014-04-11
CA3157177C (en)	2023-11-07
EP3483143A1 (en)	2019-05-15
US20160137667A1 (en)	2016-05-19
CY1121265T1 (el)	2020-05-29
RS65141B1 (sr)	2024-02-29
CO6710897A2 (es)	2013-07-15
IL223201A (en)	2015-05-31
HK1182711A1 (en)	2013-12-06
CL2016001733A1 (es)	2017-05-12
RS58366B1 (sr)	2019-03-29
HUE041488T2 (hu)	2019-05-28
EP2927213A1 (en)	2015-10-07
CL2012003415A1 (es)	2013-08-09
TW201434816A (zh)	2014-09-16
JP2016147891A (ja)	2016-08-18
MA34342B1 (fr)	2013-06-01
TN2012000559A1 (en)	2014-04-01
KR20230156431A (ko)	2023-11-14
KR20200063255A (ko)	2020-06-04
AU2011261263C1 (en)	2014-05-29
US20140011796A1 (en)	2014-01-09
JO2998B1 (ar)	2016-09-05
UA110481C2 (en)	2016-01-12
SI3483143T1 (sl)	2024-03-29
KR20190058694A (ko)	2019-05-29
EP2576510B1 (en)	2015-04-29
HK1186462A1 (en)	2014-03-14
IL223201A0 (en)	2013-02-03
TW201609649A (zh)	2016-03-16
JP2014062093A (ja)	2014-04-10
CA2799972A1 (en)	2011-12-08
PT2576510E (pt)	2015-07-01
HUE066050T2 (hu)	2024-07-28
SMT202400024T1 (it)	2024-03-13
SG10201604817QA (en)	2016-08-30
AR082763A1 (es)	2013-01-09
EP2927213B1 (en)	2018-11-14
MY202394A (en)	2024-04-25
UY39338A (es)	2021-08-31
JP2013530958A (ja)	2013-08-01
CN103180296A (zh)	2013-06-26
US20190062276A1 (en)	2019-02-28
US20260078091A1 (en)	2026-03-19
PL3483143T3 (pl)	2024-03-25
PE20130229A1 (es)	2013-03-22
CA3060703C (en)	2022-08-02
KR101863407B1 (ko)	2018-06-29
US20110319378A1 (en)	2011-12-29
EP4092012A1 (en)	2022-11-23
US20140315895A1 (en)	2014-10-23
HRP20190273T1 (hr)	2019-04-05
CA3207676A1 (en)	2011-12-08
KR20140091009A (ko)	2014-07-18
DK2927213T3 (da)	2019-03-11
TWI519519B (zh)	2016-02-01
DK2576510T3 (da)	2015-06-29
SI2576510T1 (sl)	2015-06-30
AU2011261263A1 (en)	2012-12-13
CN105153014B (zh)	2021-06-01
IL277579B (en)	2022-09-01
KR101456801B1 (ko)	2014-10-31
ES2971445T3 (es)	2024-06-05
TW201211020A (en)	2012-03-16
SG10202112488SA (en)	2021-12-30
CA3060703A1 (en)	2011-12-08
MX2012014044A (es)	2013-05-22
US20170144971A1 (en)	2017-05-25
PL2927213T3 (pl)	2019-06-28
NZ604074A (en)	2014-11-28
EA023004B1 (ru)	2016-04-29
AU2011261263B2 (en)	2013-11-21
IL265278A (en)	2019-05-30
US9296736B2 (en)	2016-03-29
NZ627385A (en)	2016-02-26
PH12012502410A1 (en)	2013-02-18
HRP20150704T1 (hr)	2015-08-14
JP5908446B2 (ja)	2016-04-26
HK1215707A1 (en)	2016-09-09
EP3483143A8 (en)	2020-04-15
CN103180296B (zh)	2015-05-27
MX343587B (es)	2016-11-10
KR20180059574A (ko)	2018-06-04
KR20210068144A (ko)	2021-06-08
ME02150B (me)	2015-10-20
US20240300892A1 (en)	2024-09-12
IL317703A (en)	2025-02-01
KR20220083817A (ko)	2022-06-20
UY33430A (es)	2011-12-30
TWI582076B (zh)	2017-05-11
PL2576510T3 (pl)	2015-10-30
WO2011153509A1 (en)	2011-12-08
US9593129B2 (en)	2017-03-14

Publication	Publication Date	Title
DK3483143T3 (da)	2024-01-15	Piperidinonderivater som mdm2-inhibitorer til behandlingen af kræft
DK2542528T3 (da)	2013-09-23	Heterocykliske amider som rock-inhibitorer
SMT201600311B (it)	2016-11-10	Inibitori di cdk
DK2406253T3 (da)	2013-08-12	Benzofuranylderivater anvendt som glucokinase-inhibitorer
DK3354652T3 (da)	2020-05-18	Piperidin-4-yl azetidinderivativer som jak1-inhibitorer
DK3520805T3 (da)	2021-04-19	Sammensætninger til behandling af myelofibrose
DK2751102T3 (da)	2019-07-01	Forbindelser og sammensætninger som C-kit-kinasehæmmere
DK3181567T3 (da)	2019-06-11	Pyrazolopyrimidinforbindelser som kinasehæmmere
DK2421825T3 (da)	2014-02-03	Azetidinyldiamider som monoacylglycerollipase-inhibitorer
DK3400944T3 (da)	2020-10-12	Ibat-inhibitorer til behandling af leversygdomme
DK2753334T3 (da)	2022-11-07	Fap-aktiverede proteasomhæmmere til behandling af solide tumorer
DK2162131T3 (da)	2013-05-27	Quinolin-derivativer som pi3-kinase-inhibitorer
DK2448938T3 (da)	2014-08-25	Pyrimidinoner som pi3k-inhibitorer
DK2558105T3 (da)	2020-01-27	Bardoxolonmethyl til behandling af fedme
DK2678329T3 (da)	2016-02-22	Triazolopyridinforbindelser som pim-kinase-hæmmere
DK3070091T3 (da)	2019-07-08	Benzodioxolderivater som phosphodiesterasehæmmere
DK2658851T3 (da)	2015-06-22	Heterocykliske forbindelser, som er egnede til behandling af dyslipidæmi
DK2825589T3 (da)	2020-08-03	Nor-hals-forbindelser som flammehæmmere